VBY 129

Drug Profile

VBY 129

Alternative Names: VBY129

Latest Information Update: 10 Dec 2015

Price : $50

At a glance

  • Originator Unknown
  • Developer Virobay
  • Class Small molecules
  • Mechanism of Action Cathepsin S inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Crohn's disease; Neuropathic pain
  • Discontinued Alzheimer's disease; Psoriasis

Most Recent Events

  • 10 Dec 2015 Discontinued for Alzheimer's disease in USA (PO)
  • 10 Dec 2015 Phase-I clinical trials in Crohn's disease in USA (PO)
  • 10 Dec 2015 Phase-I clinical trials in Neuropathic pain in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top